ViroMed of South Korea has obtained Investigational New Drug approval for VM202, its lead gene therapy drug candidate, from Korea's Ministry of Food and Drug Safety (MFDS). ViroMed will conduct a Phase II trial of the drug in 108 Korean patients with ischemic heart disease (IHD); the goal is to increase heart function by forming new blood vessels. VM202 has already started two Phase III trials: one in patients with diabetic peripheral neuropathy (DPN) and the other for ischemic diabetic foot ulcer.
